The caveolin-1 binding domain of HIV-1 glycoprotein gp41 (CBD1) contains several overlapping neutralizing epitopes

Vaccine

Volumn 27, Issue 27, 2009, Pages 3620-3630

  Benferhat, Rima ^a   Krust, Bernard ^a   Rey Cuillé, Marie Anne ^a   Hovanessian, Ara G ^a  

^a CNRS   (France)

Author keywords

Caveolin 1 binding domain; HIV 1 subunit vaccine; Immunogenic peptide; Monoclonal antibody; Overlapping neutralizing epitopes

Indexed keywords

ALANYLGLUTAMINYLTYROSYLISOLEUCYLLYSYLALANYLASPARAGINYLSERYLLYSYLPHENYLALANYLISOL EUCYLGLYCYLISOLEUCYLTHREONYLGLUTAMYLLEUCYLLYSYLLYSYLISOLEUCYLTRYPTOPHYLASPARAGIN YLASPARAGINYLMETHIONYLTHREONYLTRYPTOPHYLMETHIONYLGLUTAMINYLTRYPTOPHYLASPARTYLLYS INE; BINDING PROTEIN; CAVEOLIN 1; CAVEOLIN 1 BINDING DOMAIN; CYSTEINYLISOLEUCYLTRYPTOPHYLASPARAGINYLASPARAGINYLMETHIONYLTHREONYLTRYPTOPHYLMET HIONYLGLUTAMINYLTRYPTOPHYLASPARTYLLYSINE; CYSTEINYLSERYLLEUCYLGLUTAMYLGLUTAMINYLISOLEUCYLTRYPTOPHYLASPARAGINYLASPARAGINYLM ETHIONINE; CYSTEINYLSERYLLEUCYLGLUTAMYLGLUTAMINYLISOLEUCYLTRYPTOPHYLASPARAGINYLASPARAGINYLM ETHIONYLTHREONYLTRYPTOPHYLMETHIONYLGLUTAMINYLTRYPTOPHYLASPARTYLLYSINE; CYSTEINYLSERYLLEUCYLTHREONYLPROLYLISOLEUCYLTRYPTOPHYLASPARAGINYLASPARAGINYLMETHI ONYLTHREONYLTRYPTOPHYLGLUTAMINYLGLUTAMYLTRYPTOPHYLGLUTAMYLARGININE; EPITOPE; GLYCOPROTEIN GP 41; LYSYLARGINYLTRYPTOPHYLISOLEUCYLISOLEUCYLLYSYLGLYCYLLEUCYLASPARAGINYLLYSYLISOLEUC YLVALYLARGINYLMETHIONYLTYROSYLGLYCYLPROLYLGLYCYLPROLYLGLYCYLISOLEUCYLTRYPTOPHYLA SPARAGINYLASPARAGINYLMETHIONYLTHREONYLTRYPTOPHAN; LYSYLARGINYLTRYPTOPHYLISOLEUCYLISOLEUCYLLYSYLGLYCYLLEUCYLASPARAGINYLLYSYLISOLEUC YLVALYLARGINYLMETHIONYLTYROSYLGLYCYLPROLYLGLYCYLPROLYLGLYCYLISOLEUCYLTRYPTOPHYLA SPARAGINYLASPARAGINYLMETHIONYLTHREONYLTRYPTOPHYLMETHIONYLGLUTAMINYLTRYPTOPHAN; LYSYLARGINYLTRYPTOPHYLISOLEUCYLISOLEUCYLLYSYLGLYCYLLEUCYLASPARAGINYLLYSYLISOLEUC YLVALYLARGINYLMETHIONYLTYROSYLLYSYLLYSYLCYSTEINYLSERYLLEUCYLGLUTAMYLGLUTAMINYLIS OLEUCYLTRYPTOPHYLASPARAGINYLASPARAGINYLMETHIONINE; LYSYLARGINYLTRYPTOPHYLISOLEUCYLISOLEUCYLLYSYLGLYCYLLEUCYLASPARAGINYLLYSYLISOLEUC YLVALYLARGINYLMETHIONYLTYROSYLLYSYLLYSYLISOLEUCYLTRYPTOPHYLASPARAGINYLASPARAGINY LMETHIONINE; LYSYLARGINYLTRYPTOPHYLISOLEUCYLISOLEUCYLLYSYLGLYCYLLEUCYLASPARAGINYLLYSYLISOLEUC YLVALYLARGINYLMETHIONYLTYROSYLLYSYLLYSYLISOLEUCYLTRYPTOPHYLASPARAGINYLASPARAGINY LMETHIONYLTHREONYLTRYPTOPHAN; LYSYLARGINYLTRYPTOPHYLISOLEUCYLISOLEUCYLLYSYLGLYCYLLEUCYLASPARAGINYLLYSYLISOLEUC YLVALYLARGINYLMETHIONYLTYROSYLLYSYLLYSYLISOLEUCYLTRYPTOPHYLASPARAGINYLASPARAGINY LMETHIONYLTHREONYLTRYPTOPHYLMETHIONYLGLUTAMINYLTRYPTOPHAN; LYSYLARGINYLTRYPTOPHYLISOLEUCYLISOLEUCYLLYSYLGLYCYLLEUCYLASPARAGINYLLYSYLISOLEUC YLVALYLARGINYLMETHIONYLTYROSYLLYSYLLYSYLISOLEUCYLTRYPTOPHYLASPARAGINYLASPARAGINY LMETHIONYLTHREONYLTRYPTOPHYLMETHIONYLGLUTAMINYLTRYPTOPHYLASPARTYLLYSINE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; STRUCTURE ACTIVITY RELATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; CAVEOLIN 1; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; GUINEA PIGS; HIV ENVELOPE PROTEIN GP41; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; RABBITS;

EID: 67349146588     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.03.057     Document Type: Article

References (33)

1. McMichael A.J., and Hanke T. HIV vaccines 1983-2003. Nat Med 9 (2003) 874-880
2. McMichael A.J. HIV vaccines. Annu Rev Immunol 24 (2006) 227-255
3. Zwick M.B., and Burton D.R. HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr HIV Res 5 (2007) 608-624
4. Lin G., and Nara P.L. Designing immunogens to elicit broadly neutralizing antibodies to the HIV-1 envelope glycoprotein. Curr HIV Res 5 (2007) 514-541
5. Hovanessian A.G., Briand J.P., Said A.S., Svab J., Ferris S., Dali H., et al. The caveolin-1 binding domain of HIV-1 glycoprotein gp41 is an efficient B-cell epitope vaccine candidate against virus infection. Immunity 21 (2004) 617-627
6. Rey-Cuillé M.A., Svab J.R.B., Krust B., Briand J.P., Muller S., et al. The CBD1 epitope is an efficient B-cell epitope vaccine candidate that elicits broadly neutralizing antibodies specific to HIV-1. J Pharm Pharmacol 58 (2006) 759-767
7. Benferhat R., Martinon F., Krust B., Le Grand R., and Hovanessian A.G. The CBD1 epitope corresponding to the caveolin-1 binding domain of HIV-1 envelope glycoprotein gp41 elicits neutralizing antibodies in cynomolgus macaques when administered with the tetanus T helper epitope. Mol Immunol 46 (2009) 705-712
8. Okamoto T., Schlegel A., Scherer P.E., and Lisanti M.P. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J Biol Chem 273 (1998) 5419-5422
9. van Deurs B., Roepstorff K., Hommelgaard A.M., and Sandvig K. Caveolae: anchored, multifunctional platforms in the lipid ocean. Trends Cell Biol 13 (2003) 92-100
10. Liu P., Rudick M., and Anderson R.G.W. Multiple functions of caveolin-1. J Biol Chem 277 (2002) 41295-41298
11. Manes S., Del Real G., Lacalle R.A., Lucas P., Gomez-Mouton C., Sanchez-Palomino S., et al. Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO reports 1 (2000) 190-196
12. Nisole S., Krust B., and Hovanessian A.G. Anchorage of HIV on permissive cells leads to co-aggregation of viral particles with surface nucleolin at membrane raft microdomains. Exp Cell Res 276 (2002) 155-173
13. Nguyen D.H., and Hildreth J.E.K. Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid enriched membrane lipid rafts. J Virol 74 (2000) 3264-3272
14. Ono A., and Freed E.O. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 98 (2001) 13925-13930
15. Jolly C., and Sattentau Q. Human immunodeficiency virus type 1 virological synapse formation in T cells requires lipid raft integrity. J Virol 79 (2005) 12088-12094
16. Benferhat R., Sanchez-Martinez S., Nieva J.L., Briand J.P., and Hovanessian A.G. The immunogenic CBD1 peptide corresponding to the caveolin-1 binding domain in HIV-1 envelope gp41 has the capacity to penetrate the cell membrane and bind caveolin-1. Mol Immunol 45 (2008) 1963-1975
17. Lennon-Duménill A.M., Bakker A.H., Wolf-Bryant P., Ploegh H.L., and Lagaudrière-Gesbertr C.A. A close look at proteolysis and MHC-class-II-restricted antigen presentation. Curr Opin Immunol 14 (2002) 15-21
18. Livingston B.D., Crimi C., Newman M., Higashimoto Y., Appella E., Sidney J., et al. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitope. J Immunol 168 (2002) 5499-5506
19. Siraganian R.P., Fox P.C., and Berenstein E.H. Methods of enhancing the frequency of antign-specific hybridomas. Meth Enzymol 92 (1983) 17-26
20. 2N)PR]-TASP inhibits attachment of T-lymphocyte- and macrophage-tropic HIV to permissive cells. AIDS Res Hum Retroviruses 16 (2000) 237-249
21. Slingluff C.L.J., Yamshchikov G., Neese P., Galavotti H., Eastham S., Engelhard V.H., et al. Phase I trial of a melanomma vaccine with gp100(280-288) peptide and tetanuus helper peptide in adjuvant: immunologic and clinical outcomes. Clin Canncer Res 7 (2001) 3012-3024
22. Wilson C.C., Palmer B., Southwoood S., Sidney J., Higashimoto Y., Apella E., et al. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type-1 derived helper T-lymphocyte epitopes. J Virol 75 (2001) 4195-4207
23. Egan M.A., Chong S.Y., Hagen M., Megali S., Schadeck E.B., Piacente P., et al. A comparative evaluation of nasal and parental vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 22 (2004) 3774-3788
24. Yano A., Onozuka A., Matin K., Imai S., Hanada N., and Nisizawa T. RGD motif enhances immunogenicity and adjuvanicity of peptide antigens following intranasal immunization. Vaccine 22 (2003) 237-243
25. Yano A., Onozuka A., Asahi-Ozaki Y., Imai S., Hanada N., Miwa Y., et al. An ingenious design for peptide vaccines. Vaccine 23 (2005) 2322-2326
26. Jackson D.C., Purcell A.W., Fitzmaurice C.J., Zeng W., and Hart D.N.J. The central role played by peptides in the immune response and the design of peptide-based vaccines against infectious diseases and cancer. Curr Drug Targets 3 (2002) 175-196
27. Trombetta E.S., and Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 23 (2005) 975-1028
28. von Delwig A., Musson J.A., Gray J., McKie N., and Robinson J.H. Major histocompatibility class II molecules prevent destructive processing of exogenous peptides at the cell surface of macrophages for presentation to CD4 T cells. Immunology 114 (2005) 194-203
29. Cao C., Bai Y., Holloway M.J., Edgeworth R.L., Jackson E.A.J., Cotropia J.P., et al. Characterization of a novel human anti-HIV-1 gp41 IgM monoclonal antibody designated clone 37. DNA Cell Biol 23 (2004) 836-841
30. Steinhilb M.L., Turner R.S., and Gaut J.R. ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways. J Neurochem 80 (2002) 1019-1028
31. Parren P.W., and Burton D.R. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol 77 (2001) 195-262
32. Chen X., Rock M.T., Hammonds J., Tartaglia J., Shintani A., Currier J., et al. Pseudovirion particle production by live poxvirus human immunodeficiency virus vaccine vector enhances humoral and cellular immune responses. J Virol 79 (2005) 5537-5547
33. Belyakov I.M., and Berzofsky J.A. Immunobiology of mucosal HIV infection and the basis for development of a New generation of mucosal AIDS vaccines. Immunity 20 (2004) 247-253